Our mission is to understand how neuroinflammation contributes to pathogenesis of glaucoma, the leading cause of irreversible blindness worldwide.
Our primary focus is the role of microglia and macrophages in glaucoma, as well as their crosstalk with other cells in the retina and optic nerve microenvironment.
By developing a detailed understanding of the immune landscape in glaucoma, we hope to find novel drug targets, identify biomarkers, and ultimately develop new therapies for this devastating blinding disease.
Our team has been profiled by Mass General Brigham in The New York Times as an example of institution-wide collaboration and innovation.